These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

502 related articles for article (PubMed ID: 12429617)

  • 1. In vivo validation of 3'deoxy-3'-[(18)F]fluorothymidine ([(18)F]FLT) as a proliferation imaging tracer in humans: correlation of [(18)F]FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumors.
    Vesselle H; Grierson J; Muzi M; Pugsley JM; Schmidt RA; Rabinowitz P; Peterson LM; Vallières E; Wood DE
    Clin Cancer Res; 2002 Nov; 8(11):3315-23. PubMed ID: 12429617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lung cancer proliferation correlates with [F-18]fluorodeoxyglucose uptake by positron emission tomography.
    Vesselle H; Schmidt RA; Pugsley JM; Li M; Kohlmyer SG; Vallires E; Wood DE
    Clin Cancer Res; 2000 Oct; 6(10):3837-44. PubMed ID: 11051227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor 3'-deoxy-3'-(18)F-fluorothymidine ((18)F-FLT) uptake by PET correlates with thymidine kinase 1 expression: static and kinetic analysis of (18)F-FLT PET studies in lung tumors.
    Brockenbrough JS; Souquet T; Morihara JK; Stern JE; Hawes SE; Rasey JS; Leblond A; Wiens LW; Feng Q; Grierson J; Vesselle H
    J Nucl Med; 2011 Aug; 52(8):1181-8. PubMed ID: 21764789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of thoracic tumors with 18F-fluorothymidine and 18F-fluorodeoxyglucose-positron emission tomography.
    Yap CS; Czernin J; Fishbein MC; Cameron RB; Schiepers C; Phelps ME; Weber WA
    Chest; 2006 Feb; 129(2):393-401. PubMed ID: 16478857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG.
    Buck AK; Halter G; Schirrmeister H; Kotzerke J; Wurziger I; Glatting G; Mattfeldt T; Neumaier B; Reske SN; Hetzel M
    J Nucl Med; 2003 Sep; 44(9):1426-31. PubMed ID: 12960187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FDG uptake, glucose transporter type 1, and Ki-67 expressions in non-small-cell lung cancer: correlations and prognostic values.
    Nguyen XC; Lee WW; Chung JH; Park SY; Sung SW; Kim YK; So Y; Lee DS; Chung JK; Lee MC; Kim SE
    Eur J Radiol; 2007 May; 62(2):214-9. PubMed ID: 17239556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG.
    Chen W; Cloughesy T; Kamdar N; Satyamurthy N; Bergsneider M; Liau L; Mischel P; Czernin J; Phelps ME; Silverman DH
    J Nucl Med; 2005 Jun; 46(6):945-52. PubMed ID: 15937304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glioma proliferation as assessed by 3'-fluoro-3'-deoxy-L-thymidine positron emission tomography in patients with newly diagnosed high-grade glioma.
    Ullrich R; Backes H; Li H; Kracht L; Miletic H; Kesper K; Neumaier B; Heiss WD; Wienhard K; Jacobs AH
    Clin Cancer Res; 2008 Apr; 14(7):2049-55. PubMed ID: 18381944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histopathologic validation of 3'-deoxy-3'-18F-fluorothymidine PET in squamous cell carcinoma of the oral cavity.
    Troost EG; Bussink J; Slootweg PJ; Peeters WJ; Merkx MA; van der Kogel AJ; Oyen WJ; Kaanders JH
    J Nucl Med; 2010 May; 51(5):713-9. PubMed ID: 20395329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between non-small cell lung cancer fluorodeoxyglucose uptake at positron emission tomography and surgical stage with relevance to patient prognosis.
    Vesselle H; Turcotte E; Wiens L; Schmidt R; Takasugi JE; Lalani T; Vallières E; Wood DE
    Clin Cancer Res; 2004 Jul; 10(14):4709-16. PubMed ID: 15269143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative analysis of response to treatment with erlotinib in advanced non-small cell lung cancer using 18F-FDG and 3'-deoxy-3'-18F-fluorothymidine PET.
    Kahraman D; Scheffler M; Zander T; Nogova L; Lammertsma AA; Boellaard R; Neumaier B; Ullrich RT; Holstein A; Dietlein M; Wolf J; Kobe C
    J Nucl Med; 2011 Dec; 52(12):1871-7. PubMed ID: 22065872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Phase II Study of 3'-Deoxy-3'-18F-Fluorothymidine PET in the Assessment of Early Response of Breast Cancer to Neoadjuvant Chemotherapy: Results from ACRIN 6688.
    Kostakoglu L; Duan F; Idowu MO; Jolles PR; Bear HD; Muzi M; Cormack J; Muzi JP; Pryma DA; Specht JM; Hovanessian-Larsen L; Miliziano J; Mallett S; Shields AF; Mankoff DA;
    J Nucl Med; 2015 Nov; 56(11):1681-9. PubMed ID: 26359256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluorodeoxyglucose uptake of primary non-small cell lung cancer at positron emission tomography: new contrary data on prognostic role.
    Vesselle H; Freeman JD; Wiens L; Stern J; Nguyen HQ; Hawes SE; Bastian P; Salskov A; Vallières E; Wood DE
    Clin Cancer Res; 2007 Jun; 13(11):3255-63. PubMed ID: 17545531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation of the standardized uptake value in FDG-PET with the expression level of cell-cycle-related molecular biomarkers in resected non-small cell lung cancers.
    Nakamura H; Hirata T; Kitamura H; Nishikawa J
    Ann Thorac Cardiovasc Surg; 2009 Oct; 15(5):304-10. PubMed ID: 19901884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation of 18F-FLT and 18F-FDG uptake on PET with Ki-67 immunohistochemistry in non-small cell lung cancer.
    Yamamoto Y; Nishiyama Y; Ishikawa S; Nakano J; Chang SS; Bandoh S; Kanaji N; Haba R; Kushida Y; Ohkawa M
    Eur J Nucl Med Mol Imaging; 2007 Oct; 34(10):1610-6. PubMed ID: 17530250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 3-deoxy-3-[(18)F]fluorothymidine-positron emission tomography for noninvasive assessment of proliferation in pulmonary nodules.
    Buck AK; Schirrmeister H; Hetzel M; Von Der Heide M; Halter G; Glatting G; Mattfeldt T; Liewald F; Reske SN; Neumaier B
    Cancer Res; 2002 Jun; 62(12):3331-4. PubMed ID: 12067968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlations of (18)F-fluorothymidine uptake with pathological tumour size, Ki-67 and thymidine kinase 1 expressions in primary and metastatic lymph node colorectal cancer foci.
    Nakajo M; Nakajo M; Kajiya Y; Goto Y; Jinguji M; Tanaka S; Fukukura Y; Tani A; Higashi M
    Eur Radiol; 2014 Dec; 24(12):3199-209. PubMed ID: 25120206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imaging cellular proliferation during chemo-radiotherapy: a pilot study of serial 18F-FLT positron emission tomography/computed tomography imaging for non-small-cell lung cancer.
    Everitt S; Hicks RJ; Ball D; Kron T; Schneider-Kolsky M; Walter T; Binns D; Mac Manus M
    Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1098-104. PubMed ID: 19386444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation between Ki-67 immunohistochemistry and 18F-fluorothymidine uptake in patients with cancer: A systematic review and meta-analysis.
    Chalkidou A; Landau DB; Odell EW; Cornelius VR; O'Doherty MJ; Marsden PK
    Eur J Cancer; 2012 Dec; 48(18):3499-513. PubMed ID: 22658807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of simplified methods to measure 18F-FLT uptake changes in EGFR-mutated non-small cell lung cancer patients undergoing EGFR tyrosine kinase inhibitor treatment.
    Frings V; Yaqub M; Hoyng LL; Golla SS; Windhorst AD; Schuit RC; Lammertsma AA; Hoekstra OS; Smit EF; Boellaard R;
    J Nucl Med; 2014 Sep; 55(9):1417-23. PubMed ID: 24970910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.